GO:0048019 receptor antagonist activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048019 receptor antagonist activity describes the molecular function of a gene product that binds a receptor and decreases the ability of the receptor agonist to bind and activate that receptor.
• Receptor antagonists can act competitively, allosterically, or by stabilizing inactive receptor conformations, and they are widely used as pharmacological tools and therapeutic agents.
• Endogenous receptor antagonists, such as leptin antagonist and H2S signaling modulators, regulate energy homeostasis and vascular aging.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of receptor antagonist activity in disease contexts.
• Dysregulated receptor antagonist activity contributes to sarcopenia, depression, obesity, and vascular aging.
• EDITGENE provides end-to-end CRISPR services, including KO, point mutation, knock-in, overexpression, library screening, and bioinformatics, to study receptor antagonist activity.
Description
GO:0048019 receptor antagonist activity is a molecular function term in the Gene Ontology that defines the activity of a gene product which interacts with a receptor to decrease the ability of the receptor agonist to bind and activate the receptor. This term captures a fundamental regulatory mechanism in cell signaling, where endogenous or exogenous molecules modulate receptor function without necessarily activating it. Receptor antagonists are critical for understanding how signaling pathways are fine-tuned and how pharmacological interventions can alter disease trajectories. The concept spans multiple receptor families, including G-protein-coupled receptors, cytokine receptors, and neurotransmitter receptors, and is essential for interpreting both physiological and pathological states. In biomedical research, receptor antagonist activity is studied to dissect signaling cascades, identify drug targets, and develop therapeutics for conditions such as depression, obesity, sarcopenia, and vascular aging. For example, the pituitary adenylate cyclase-activating polypeptide receptor antagonist PA-915 produces rapid antidepressant-like effects in chronic stress mouse models, while central overexpression of leptin antagonist reduces wheel running and underscores the importance of endogenous leptin receptor activity in energy homeostasis. These findings highlight how receptor antagonist activity can be harnessed to probe and manipulate biological systems. Understanding GO:0048019 also requires distinguishing it from receptor agonist activity and receptor ligand activity. The QuickGO definition emphasizes the decrease in agonist binding and activation, which can occur through competitive binding, allosteric modulation, or receptor internalization. This functional annotation is supported by experimental evidence from pharmacological and genetic studies, and it is increasingly relevant for CRISPR-based screens and precision medicine approaches.
receptor antagonist activity At A Glance
| GO ID | GO:0048019 |
|---|---|
| GO term | receptor antagonist activity |
| Ontology | molecular_function |
| Synonym | receptor ligand activity |
| Definition | The activity of a gene product that interacts with a receptor to decrease the ability of the receptor agonist to bind and activate the receptor. |
| Major function | Negative regulation of receptor signaling by blocking agonist binding or activation. |
| Examples | Leptin antagonist, PACAP receptor antagonist PA-915, metabotropic glutamate receptor antagonist LY3020371, D1 receptor antagonist SCH-23390. |
| Related terms | Receptor agonist activity, receptor ligand activity, receptor binding. |
| Research relevance | Target for drug discovery, CRISPR screens, and disease modeling in depression, obesity, and vascular aging. |
What Is GO:0048019?
In simple terms, receptor antagonist activity is the function of a molecule that blocks or dampens a receptor's response to its natural activator. According to the Gene Ontology, GO:0048019 is defined as the activity of a gene product that interacts with a receptor to decrease the ability of the receptor agonist to bind and activate the receptor. This activity does not require the antagonist to activate the receptor; instead, it reduces the efficacy or potency of the agonist. Antagonists can be competitive, binding the same site as the agonist, or non-competitive, binding elsewhere to prevent activation. The term is classified under molecular_function and is synonymous with receptor ligand activity in some contexts.
Why Is receptor antagonist activity Important in Cell Biology?
Receptor antagonist activity is central to pharmacology and physiology because it provides a mechanism to selectively dampen overactive signaling pathways. Many therapeutic drugs are receptor antagonists, and endogenous antagonists regulate processes such as energy balance, mood, and vascular tone. Studying GO:0048019 helps researchers identify new drug targets, understand resistance mechanisms, and design CRISPR models that mimic human disease states.
• Receptor antagonists are used to treat depression, as shown by PA-915 in chronic stress models.
• Leptin antagonist overexpression reduces physical activity, highlighting leptin receptor activity in energy homeostasis.
• Endothelial NAD+-H2S signaling network impairment is a reversible cause of vascular aging, involving receptor antagonist-like mechanisms.
• Rimonabant, a cannabinoid receptor antagonist, prevents antidepressant-induced weight gain without interfering with behavioral effectiveness.
• SCH-23390, a D1 receptor antagonist, differentially affects swimming activity and anxiety-related responses in zebrafish.
• LY3020371, a metabotropic glutamate 2/3 receptor antagonist, shows antidepressant-like activity.
• Sarcopenia pathophysiology involves altered receptor signaling that can be targeted by antagonists.
• CRISPR knockout of receptor genes can reveal endogenous antagonist activity.
• Receptor antagonist activity is a key annotation for functional genomics and drug repurposing screens.
• Understanding antagonist mechanisms aids in designing biased ligands and allosteric modulators.
Molecular Mechanism of receptor antagonist activity
Agonist binding and receptor activation
In simple terms: First, the natural activator binds the receptor and turns it on.
Receptor activation typically begins with agonist binding, which induces conformational changes that propagate to intracellular domains and trigger signaling. In the context of GO:0048019, the antagonist interferes with this step by reducing agonist binding or preventing the active conformation. For example, PACAP receptor antagonist PA-915 blocks PACAP-induced signaling in chronic stress models.
Competitive antagonism
In simple terms: The antagonist competes with the agonist for the same binding site.
Competitive antagonists bind the orthosteric site of the receptor, directly competing with the agonist and reducing the fraction of receptors occupied by agonist at a given concentration. This mechanism is exemplified by SCH-23390, a D1 receptor antagonist that alters swimming activity and anxiety-related responses in zebrafish. The QuickGO definition encompasses this mode by stating that the antagonist decreases the ability of the agonist to bind and activate the receptor.
Allosteric and non-competitive antagonism
In simple terms: The antagonist binds a different site and changes the receptor shape.
Allosteric antagonists bind outside the orthosteric pocket and stabilize inactive receptor conformations or prevent conformational transitions required for activation. LY3020371, a metabotropic glutamate 2/3 receptor antagonist, demonstrates antidepressant-like activity through such mechanisms. These antagonists can reduce agonist efficacy without competing for the binding site, and they are captured by GO:0048019 because they decrease receptor activation.
Endogenous antagonists and physiological regulation
In simple terms: The body makes its own antagonists to keep signaling in check.
Endogenous antagonists such as leptin antagonist regulate energy homeostasis; central overexpression of leptin antagonist reduces wheel running and underscores the importance of endogenous leptin receptor activity. Similarly, the endothelial NAD+-H2S signaling network involves antagonist-like regulation that is a reversible cause of vascular aging. These examples show that receptor antagonist activity is not only pharmacological but also a physiological regulatory mechanism.
Receptor internalization and downregulation
In simple terms: Some antagonists cause the receptor to be removed from the cell surface.
Certain antagonists can induce receptor internalization or downregulation, thereby reducing the available receptor pool for agonist binding. This long-term effect can contribute to the decrease in agonist-mediated activation described in GO:0048019. While direct evidence for this mechanism in the cited papers is limited, the concept is consistent with the definition and with pharmacological observations in depression and metabolic studies.
Key Genes Involved in GO:0048019 receptor antagonist activity
The following genes and proteins are experimentally linked to receptor antagonist activity or are commonly used as models to study this function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LEP | Leptin hormone; its antagonist blocks leptin receptor | Central overexpression of leptin antagonist reduces wheel running |
| LEPR | Leptin receptor; target of leptin antagonist | Endogenous leptin receptor activity in energy homeostasis |
| ADCYAP1R1 | PACAP receptor; blocked by PA-915 | Antidepressant-like effects in chronic stress models |
| GRM2 | Metabotropic glutamate receptor 2; target of LY3020371 | Antidepressant-like activity |
| GRM3 | Metabotropic glutamate receptor 3; target of LY3020371 | Antidepressant-like activity |
| DRD1 | Dopamine D1 receptor; blocked by SCH-23390 | Swimming activity and anxiety-related responses in zebrafish |
| CNR1 | Cannabinoid receptor 1; blocked by rimonabant | Prevention of antidepressant-induced weight gain |
| BDNF | Neurotrophic factor; modulated by exercise and ketone bodies | Exercise promotes BDNF expression via β-hydroxybutyrate |
| CBS | Cystathionine beta-synthase; H2S production | Endothelial NAD+-H2S signaling network in vascular aging |
| CSE | Cystathionine gamma-lyase; H2S production | Endothelial NAD+-H2S signaling network in vascular aging |
| NMNAT | NAD+ biosynthesis enzyme | Vascular aging and NAD+ decline |
| SIRT1 | NAD+-dependent deacetylase | Vascular aging and NAD+ signaling |
| MSTN | Myostatin; antagonist approaches in sarcopenia | Sarcopenia pathophysiology and treatment |
| IGF1 | Insulin-like growth factor 1; receptor antagonist contexts | Sarcopenia and muscle homeostasis |
| TNF | Tumor necrosis factor; receptor antagonist therapies | Inflammatory signaling in sarcopenia |
| IL6 | Interleukin-6; receptor antagonist contexts | Inflammation and muscle wasting |
| PA-915 target (ADCYAP1R1) | PACAP receptor antagonist | Rapid antidepressant-like effects |
How Is receptor antagonist activity Regulated?
Receptor antagonist activity is regulated at multiple levels, including antagonist expression, receptor availability, and downstream signaling feedback. For example, central overexpression of leptin antagonist reduces wheel running, indicating that endogenous antagonist levels can modulate behavior and energy homeostasis. The endothelial NAD+-H2S signaling network is a reversible regulator of vascular aging, where antagonist-like mechanisms influence NAD+ levels and sirtuin activity. In pharmacological contexts, antidepressant-induced weight gain can be prevented by rimonabant without interfering with behavioral effectiveness, showing that antagonist activity can be selectively regulated. Additionally, exercise promotes BDNF expression through β-hydroxybutyrate, which may interact with receptor antagonist pathways.
receptor antagonist activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADCYAP1R1 | Depression, stress-related disorders | PACAP receptor antagonist PA-915 in chronic stress mouse models |
| LEP | Obesity, energy homeostasis | Central overexpression of leptin antagonist in rodents |
| CNR1 | Antidepressant-induced weight gain | Rimonabant treatment in animal models |
| GRM2/GRM3 | Depression | LY3020371 in antidepressant-like activity assays |
| CBS/CSE | Vascular aging | Endothelial NAD+-H2S signaling network models |
Depression and stress-related disorders
Receptor antagonist activity is directly implicated in depression. The PACAP receptor antagonist PA-915 produces rapid and long-lasting antidepressant-like effects in chronic stress mouse models. Similarly, the metabotropic glutamate 2/3 receptor antagonist LY3020371 shows antidepressant-like activity. These findings suggest that blocking specific receptors can reverse stress-induced behavioral deficits, making GO:0048019 a key annotation for neuropsychiatric drug discovery.
Obesity and metabolic disorders
Leptin antagonist overexpression reduces wheel running and underscores the importance of endogenous leptin receptor activity in energy homeostasis. Rimonabant, a cannabinoid receptor antagonist, prevents antidepressant-induced weight gain without interfering with behavioral effectiveness. These studies link receptor antagonist activity to metabolic regulation and highlight potential therapeutic strategies for obesity and weight management.
Vascular aging and sarcopenia
Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging, involving antagonist-like regulation of receptor signaling. Sarcopenia pathophysiology also involves altered receptor signaling that can be targeted by antagonists, as reviewed in the context of diagnosis and treatment. These conditions illustrate how receptor antagonist activity contributes to age-related tissue dysfunction.
From receptor antagonist activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a receptor gene mimic antagonist effects? | CRISPR knockout cell lines or animal models |
| Can a point mutation in the receptor abolish antagonist binding? | CRISPR point mutation knock-in models |
| Does overexpression of an endogenous antagonist alter behavior? | Transgenic overexpression models |
| Can a tagged antagonist be used for imaging? | Knock-in of tagged antagonist |
| Which genes regulate receptor antagonist activity? | CRISPR library screening |
| Does pharmacological antagonist treatment reverse disease phenotypes? | Pharmacological intervention in disease models |
How to Study the receptor antagonist activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Competitive displacement of agonist | Quantify antagonist affinity |
| cAMP/Ca2+ flux | Receptor activation | Functional antagonism assays |
| CRISPR knockout | Gene function loss | Test receptor or antagonist necessity |
| Behavioral tests | Locomotor activity, anxiety | Zebrafish and rodent models |
| Western blot | Protein expression and phosphorylation | Downstream signaling |
| Immunoprecipitation | Protein-protein interactions | Receptor-antagonist complexes |
| RNA-seq | Transcriptomic changes | Global effects of antagonist treatment |
Pharmacological assays
Receptor antagonist activity is often measured using pharmacological assays such as radioligand binding, cAMP accumulation, or calcium flux. For example, PA-915 was tested for antidepressant-like effects in chronic stress mouse models, and LY3020371 was characterized for metabotropic glutamate receptor antagonism. These assays quantify the ability of a compound to decrease agonist-induced receptor activation, directly reflecting GO:0048019.
Genetic knockout and knockdown
CRISPR knockout or RNA interference can eliminate receptor or antagonist expression to test causality. Central overexpression of leptin antagonist reduces wheel running, demonstrating the role of endogenous leptin receptor activity. Knockout of receptors such as ADCYAP1R1 can mimic antagonist effects and validate target engagement.
Behavioral and physiological readouts
Behavioral tests in zebrafish and rodents assess the functional consequences of receptor antagonist activity. SCH-23390, a D1 receptor antagonist, differentially affects swimming activity and anxiety-related responses in zebrafish. In rodents, rimonabant prevents antidepressant-induced weight gain without interfering with behavioral effectiveness. These readouts link molecular function to organismal phenotypes.
Molecular signaling analysis
Western blotting, immunoprecipitation, and reporter assays can measure downstream signaling changes upon antagonist treatment. The endothelial NAD+-H2S signaling network involves reversible modulation of NAD+ levels and sirtuin activity, which can be assessed by biochemical assays. Exercise-induced BDNF expression via β-hydroxybutyrate also involves signaling cascades that intersect with receptor antagonist pathways.
How CRISPR Can Be Used to Study GO:0048019 receptor antagonist activity
Knockout
CRISPR knockout of receptor genes or endogenous antagonists can reveal their role in signaling. For example, knocking out ADCYAP1R1 would mimic the effects of PA-915 and test whether the receptor is required for antidepressant-like responses. Knockout of leptin or its receptor can validate the effects of leptin antagonist on energy homeostasis.
Point Mutation
Point mutations in the receptor binding pocket can abolish antagonist binding while preserving agonist responses, allowing precise dissection of GO:0048019. Such models are useful for studying competitive versus allosteric antagonism. For instance, mutating residues in DRD1 that interact with SCH-23390 could clarify its mechanism.
Knock-in
Knock-in of tagged receptors or antagonists enables imaging and biochemical tracking. A tagged leptin antagonist could be knocked into the endogenous locus to study its trafficking and interaction with LEPR. Similarly, knock-in of fluorescently labeled PACAP receptor can visualize PA-915 binding.
Overexpression
Overexpression of an endogenous antagonist, such as leptin antagonist, can phenocopy antagonist treatment and reveal physiological consequences. Central overexpression of leptin antagonist reduces wheel running, demonstrating the importance of endogenous leptin receptor activity. Overexpression models are also useful for screening antagonist candidates.
How EDITGENE Supports receptor antagonist activity Research
Researchers studying receptor antagonist activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. CRISPR-based models provide a robust way to test loss-of-function, gain-of-function, and precise mutations in receptors or their antagonists. EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for receptor antagonist activity research.
Frequently Asked Questions About receptor antagonist activity
What is receptor antagonist activity?
Receptor antagonist activity (GO:0048019) is the function of a gene product that interacts with a receptor to decrease the ability of the receptor agonist to bind and activate the receptor.
What genes are involved in receptor antagonist activity?
Genes include LEP, LEPR, ADCYAP1R1, GRM2, GRM3, DRD1, and CNR1, among others, as shown in pharmacological and genetic studies.
How is receptor antagonist activity different from receptor agonist activity?
An agonist activates the receptor, while an antagonist decreases agonist binding and activation without necessarily activating the receptor.
What diseases are linked to receptor antagonist activity?
Depression, obesity, vascular aging, and sarcopenia are linked to receptor antagonist activity through pathways involving PACAP, leptin, cannabinoid, and H2S signaling.
Can CRISPR be used to study receptor antagonist activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of receptors and antagonists in signaling and disease.
What is an example of a receptor antagonist drug?
Rimonabant is a cannabinoid receptor antagonist that prevents antidepressant-induced weight gain, and PA-915 is a PACAP receptor antagonist with antidepressant-like effects.
How do you measure receptor antagonist activity?
Common methods include radioligand binding, cAMP/Ca2+ flux assays, and behavioral tests in animal models.
Is receptor antagonist activity a molecular function?
Yes, GO:0048019 is classified under molecular_function in the Gene Ontology.
What is the synonym for receptor antagonist activity?
The synonym is receptor ligand activity, as listed in QuickGO.
Why is receptor antagonist activity important for drug discovery?
It provides a mechanism to selectively block overactive signaling pathways, as demonstrated by antidepressants and metabolic drugs.
Conclusion
GO:0048019 receptor antagonist activity is a fundamental molecular function that regulates receptor signaling by decreasing agonist binding and activation. It is experimentally linked to depression, obesity, vascular aging, and sarcopenia, and it is a key target for pharmacological and CRISPR-based research. Understanding its mechanisms and regulation can guide the development of new therapeutics and precision disease models. EDITGENE supports this research with comprehensive CRISPR services, including knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics, enabling researchers to dissect receptor antagonist activity in any biological context.
References
- 1. Cho MR et al.. 2022. A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction.. J Korean Med Sci 37(18):e146 PMID: 35535373
- 2. Das A et al.. 2018. Impairment of an Endothelial NAD(+)-H(2)S Signaling Network Is a Reversible Cause of Vascular Aging.. Cell 173(1):74-89.e20 PMID: 29570999
- 3. Shintani Y et al.. 2026. Rapid and long-lasting antidepressant-like effects of the pituitary adenylate cyclase-activating polypeptide receptor antagonist PA-915 in chronic stress mouse models.. Mol Psychiatry 31(2):1014-1026 PMID: 40908362
- 4. Sleiman SF et al.. 2016. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate.. Elife 5 PMID: 27253067
- 5. Gobshtis N et al.. 2007. Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.. Eur J Pharmacol 554(2-3):155-63 PMID: 17116301
- 6. Matheny M et al.. 2009. Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis.. Am J Physiol Regul Integr Comp Physiol 297(5):R1254-61 PMID: 19726711
- 7. Tran S et al.. 2015. Differential effects of acute administration of SCH-23390, a D₁ receptor antagonist, and of ethanol on swimming activity, anxiety-related responses, and neurochemistry of zebrafish.. Psychopharmacology (Berl) 232(20):3709-18 PMID: 26210378
- 8. Chappell MD et al.. 2016. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.. J Med Chem 59(24):10974-10993 PMID: 28002967
